Clinical-stage psychedelics biotech Reunion Neuroscience (NASDAQ: REUN) and MPM BioImpact have completed their announced plan of arrangement for MPM&rsq
ePlus inc. (NASDAQ NQGS: PLUS – news) today announced that its board of directors has authorized the Company to repurchase up to 1,000,000 shares of ePlus' outstanding common stock over a